Condition: Waldenstrom's Disease · Prognostic Index · Sponsor: French Innovative Leukemia Organisation
Waldenström's macroglobulinemia (WM) is defined by the association of bone marrow lymphoplasmocytic infiltration and monoclonal immunoglobulin M (IgM). A mutation in the MYD88 gene is found in up to 90% of patients, and a mutation in the CXCR4 gene in approximately one third of patients. Treatment should be initiated in cases of cytopenia, bulky disease or when the physicochemical or immunological properties of IgM explain the occurrence of amyloidosis, cryoglobulin, neurological manifestations, or hyperviscosity syndrome (due to the presence of a large amount of IgM). However, approximately 30% of patients are diagnosed without any symptom and therefore they do not meet the criteria for initiating treatment. At the time of initiation of the first treatment, the prognosis is usually estimated with the International Prognostic Index (IPSSWM) which is based on five variables: age, platelet count, haemoglobin concentrations, β2-microglobulin and monoclonal component concentration. Serum albumin and lactate dehydrogénase (LDH) levels also retain a prognostic role and these two characteristics have been incorporated in a proposal for a revision of this index. Improving prognostic assessment at the time of the first treatment initiation and taking into account the prognostic impact of events occurring in the course of evolution, should improve the strength of treatment decision at the time of initial treatment and during the follow-up. It should also help to design clinical trial…
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| AMIENS - CH Amiens Picardie Site Sud | Amiens, France | Not Yet Recruiting |
| Angers Chu | Angers, France | Not Yet Recruiting |
| Institut Bergonie | Bordeaux, France | Not Yet Recruiting |
| Clermont-Ferrand - Chu Estaing | Clermont-Ferrand, France | Not Yet Recruiting |
| Le Mans CH | Le Mans, France | Not Yet Recruiting |
| LENS - GHT Artois | Lens, France | Not Yet Recruiting |
| LIBOURNE - Hôpital Robert Boulin | Libourne, France | Not Yet Recruiting |
| LILLE GHICL - Hôpital Saint Vincent de Paul | Lille, France | Recruiting |
| Institut Paoli Calmette | Marseille, France | Not Yet Recruiting |
| APHP - Hôpital Pitié Salpêtrière - Hématologie | Paris, France | Not Yet Recruiting |
| POITIERS - Hématologie et Thérapie Cellulaire | Poitiers, France | Not Yet Recruiting |
| Reims Chu | Reims, France | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05911802